In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Blueprint Medicines Corp (NASDAQ: BPMC) closed at $101.39 in the last session, up 1.77% from day before closing price of $99.63. In other words, the price has increased by $1.77 from its previous closing price. On the day, 0.7 million shares were traded. BPMC stock price reached its highest trading level at $102.465 during the session, while it also had its lowest trading level at $98.59.
Ratios:
We take a closer look at BPMC’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.27 and its Current Ratio is at 3.32. In the meantime, Its Debt-to-Equity ratio is 2.34 whereas as Long-Term Debt/Eq ratio is at 1.96.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, UBS on October 24, 2024, initiated with a Neutral rating and assigned the stock a target price of $88.
On May 14, 2024, Stephens started tracking the stock assigning a Overweight rating and target price of $140.
Leerink Partners Upgraded its Underperform to Market Perform on May 06, 2024, whereas the target price for the stock was revised from $50 to $97.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 07 ’24 when Albers Jeffrey W. bought 5,000 shares for $102.00 per share.
Namouni Fouad sold 3,633 shares of BPMC for $324,500 on Oct 03 ’24. The PRESIDENT, R & D now owns 69,070 shares after completing the transaction at $89.32 per share. On Sep 09 ’24, another insider, Albers Jeffrey W., who serves as the Director of the company, sold 19,702 shares for $85.57 each. As a result, the insider received 1,685,891 and left with 157,557 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BPMC now has a Market Capitalization of 6440880640 and an Enterprise Value of 6439414784. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.83 while its Price-to-Book (P/B) ratio in mrq is 20.55. Its current Enterprise Value per Revenue stands at 14.823 whereas that against EBITDA is -24.566.
Stock Price History:
Over the past 52 weeks, BPMC has reached a high of $121.90, while it has fallen to a 52-week low of $56.74. The 50-Day Moving Average of the stock is 13.84%, while the 200-Day Moving Average is calculated to be 6.47%.
Shares Statistics:
According to the various share statistics, BPMC traded on average about 616.29K shares per day over the past 3-months and 878510 shares per day over the past 10 days. A total of 63.53M shares are outstanding, with a floating share count of 62.37M. Insiders hold about 1.82% of the company’s shares, while institutions hold 104.93% stake in the company. Shares short for BPMC as of 1728950400 were 3619115 with a Short Ratio of 5.87, compared to 1726185600 on 3666657. Therefore, it implies a Short% of Shares Outstanding of 3619115 and a Short% of Float of 6.43.
